If a drug derived from the milk of transgenic animals is commercialized, GTC will presumably seek to license its “milk” patent for an up-front fee and/or a royalty on sales. The terms will have to be negotiated.
Research and clinical-trial use of a drug candidate is exempt from U.S. patent infringement, so there isn’t much for the parties to talk about until such a drug is commercialized or on the verge of being commercialized. Regards, Dew
News 
Market Data 
Discover 
AI
